We have a strong potential therapy for Covid - (and I admit that there are hundreds more compounds chasing this same market) - last weeks market movement was abysmal given the circumstances - RVX should deserve better but absolutely no volume or interest - Why?

This is just an opinion and my observations on the dynamics of the ownership in RVX - 

DM is the keystone that keeps Hepa and Eastern at arms length.

Remove the keystone and there will be a Hepa takeover.

DM has done a marvelous job funding the growth of the company without acquiescing control. Enter the Shiek - a new source of capital not aligned with Hepa or Eastern giving Resverlogix funds to continue until a BP partnership or buyout. The dynamics of Hepa make for a difficult engagement or marriage with BP

jmo

Chicagoest